Kanada - enska - Health Canada

marcan pharmaceuticals inc - melphalan (melphalan hydrochloride); buffer solution - solution - 50mg; 10ml - melphalan (melphalan hydrochloride) 50mg; buffer solution 10ml - antineoplastic agents

Kanada - enska - Health Canada

apotex inc - melphalan (melphalan hydrochloride); buffer solution - solution - 50mg; 10ml - melphalan (melphalan hydrochloride) 50mg; buffer solution 10ml - antineoplastic agents

Kanada - enska - Health Canada

juno pharmaceuticals corp. - melphalan (melphalan hydrochloride) - kit - 50mg - melphalan (melphalan hydrochloride) 50mg

Kanada - enska - Health Canada

auro pharma inc - melphalan (melphalan hydrochloride) - kit - 50mg - melphalan (melphalan hydrochloride) 50mg - antineoplastic agents

Kanada - enska - Health Canada

eugia pharma inc. - melphalan (melphalan hydrochloride) - kit - 50mg - melphalan (melphalan hydrochloride) 50mg

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - melphalan 50mg - solution for injection - 50 mg - active: melphalan 50mg excipient: hydrochloric acid povidone ethanol propylene glycol sodium citrate dihydrate

Bandaríkin - enska - NLM (National Library of Medicine)

sagent pharmaceuticals - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan should not be used in patients whose disease has demonstrated prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aspen pharma trading ltd. - melphalan 50 mg - powder and solvent for solution for infusion - 50 mg - melphalan 50 mg - melphalan

Bandaríkin - enska - NLM (National Library of Medicine)

fosun pharma usa inc - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. melphalan should not be used in patients whose disease has demonstrated prior resistance to this agent. patients who have demonstrated hypersensitivity to melphalan should not be given the drug.

Bandaríkin - enska - NLM (National Library of Medicine)

acrotech biopharma llc - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml - evomela is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. history of serious allergic reaction to melphalan. risk summary based on its mechanism of action, evomela can cause fetal harm when administered to a pregnant woman, including teratogenicity and/or embryo-fetal lethality [see clinical pharmacology (12.1)] . melphalan is a genotoxic drug and can cause chromatid or chromosome damage in humans [see nonclinical toxicology (13.1)] . in animal studies, melphalan was embryolethal and teratogenic in rats at doses below the recommended clinical doses [see data] . advise a pregnant woman of the potential risk to a fetus.. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk in the u.s. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. data   animal data adequate ani